Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations

@inproceedings{Dobbin2016ValidationOB,
  title={Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations},
  author={K. K. Dobbin and Alessandra Cesano and John D. Alvarez and Rachael Elizabeth Hawtin and Sylvia Janetzki and Ilan R. Kirsch and Giuseppe V Masucci and Paul B. Robbins and Senthamil R Selvan and Howard Z. Streicher and Jenny Zhang and Lisa H Butterfield and Magdalena Thurin},
  booktitle={Journal for immunotherapy of cancer},
  year={2016}
}
There is growing recognition that immunotherapy is likely to significantly improve health outcomes for cancer patients in the coming years. Currently, while a subset of patients experience substantial clinical benefit in response to different immunotherapeutic approaches, the majority of patients do not but are still exposed to the significant drug toxicities. Therefore, a growing need for the development and clinical use of predictive biomarkers exists in the field of cancer immunotherapy… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 18 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

and Drug Administration

  • US Foo
  • List of cleared or approved companion diagnostic…
  • 2016

Similar Papers

Loading similar papers…